MetaADEDB 2.0 @ LMMD
Alitretinoin
(SHGAZHPCJJPHSC-ZVCIMWCZSA-N)
Structure
SMILES
C/C(=C/C=C/C(=C/C(=O)O)/C)/C=C/C1=C(C)CCCC1(C)C
Type(s)
Approved; Investigational
ATC code(s)
D11AH04; L01XX22
Molecular Formula:
C20H28O2
Molecular Weight:
300.435
Log P:
5.6026
Hydrogen Bond Acceptor:
2
Hydrogen Bond Donor:
1
TPSA:
37.3
CAS Number(s):
5300-03-8; 1241893
Synonym(s)
1.
Alitretinoin
2.
9-cis-Retinoic Acid
3.
9cRA Compound
4.
BAL4079
5.
Panretin
6.
Toctino
7.
9 cis Retinoic Acid
External Link(s)
MeSHD000077556
PubChem Compound449171
BindingDB31892
ChEBI50648
CHEMBLCHEMBL705
DrugBankDB00523
DrugCentral3862
IUPHAR/BPS Guide to PHARMACOLOGY2645
5383
KEGGcpd:C15493
dr:D02815
Therapeutic Target DatabaseD0G3PI
D09RQU
D0Y3LW
ZINC12661824
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 1US FAERS
2Intestinal ObstructionFAERS: 1US FAERS
3Myocardial InfarctionFAERS: 1US FAERS
4PancreatitisFAERS: 1US FAERS
5Product storage errorFAERS: 1US FAERS
6AgitationCanada Vigilance: 1Canada Vigilance
7AngioedemaCanada Vigilance: 1Canada Vigilance
8AnxietyCanada Vigilance: 4Canada Vigilance
9AstheniaCanada Vigilance: 2Canada Vigilance
10Blood cholesterol increasedCanada Vigilance: 1Canada Vigilance
11Blood triglycerides increasedCanada Vigilance: 2Canada Vigilance
12BronchitisCanada Vigilance: 1Canada Vigilance
13Chemical and Drug Induced Liver Injury11595692CTD
14ChillsCanada Vigilance: 1Canada Vigilance
15ConstipationCanada Vigilance: 1Canada Vigilance
16Deafness NeurosensoryCanada Vigilance: 1Canada Vigilance
17Depressed moodCanada Vigilance: 2Canada Vigilance
18DiplopiaCanada Vigilance: 1Canada Vigilance
19DizzinessCanada Vigilance: 1Canada Vigilance
20Eczema10640839CTD
21Emotional povertyCanada Vigilance: 1Canada Vigilance
22ErythemaCanada Vigilance: 1Canada Vigilance
23FatigueCanada Vigilance: 4Canada Vigilance
24Gastrointestinal PainCanada Vigilance: 1Canada Vigilance
25HeadacheCanada Vigilance: 511595692CTD
Canada Vigilance
26HypersomniaCanada Vigilance: 1Canada Vigilance
27Irritable Bowel SyndromeCanada Vigilance: 1Canada Vigilance
28Lung Neoplasms16413115CTD
29MalaiseCanada Vigilance: 1Canada Vigilance
30Memory impairmentCanada Vigilance: 1Canada Vigilance
31MetamorphopsiaCanada Vigilance: 1Canada Vigilance
32Morbid thoughtsCanada Vigilance: 1Canada Vigilance
33MyalgiaCanada Vigilance: 1Canada Vigilance
34NauseaCanada Vigilance: 1Canada Vigilance
35Neoplasms16946489CTD
36Peripheral swellingCanada Vigilance: 1Canada Vigilance
37Porokeratosis16144296CTD
38Product quality issueCanada Vigilance: 1Canada Vigilance
39Prostatic Neoplasms20932324CTD
40PruritusCanada Vigilance: 1Canada Vigilance
41Pseudotumor Cerebri11595692CTD
42PsoriasisCanada Vigilance: 1Canada Vigilance
43Pyoderma GangrenosumCanada Vigilance: 1Canada Vigilance
44ReticulocytopeniaCanada Vigilance: 1Canada Vigilance
45SyncopeCanada Vigilance: 1Canada Vigilance
46TensionCanada Vigilance: 1Canada Vigilance
47Throat irritationCanada Vigilance: 1Canada Vigilance
48TinnitusCanada Vigilance: 1Canada Vigilance
49Urinary IncontinenceCanada Vigilance: 1Canada Vigilance
50UrticariaCanada Vigilance: 1Canada Vigilance
51VomitingCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.